This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Brodalumab injection

Updated 2 Feb 2023 | Brodalumab


Injections of brodalumab.

These products have been produced by recombinant technology using Chinese Hamster Ovary (CHO) cell lines.

Drugs List

  • brodalumab pre-filled syringe 210mg/1.5ml injection solution
  • KYNTHEUM PRE-FILLED SYRINGE 210mg/1.5ml injection solution
  • Therapeutic Indications


    Moderate to severe plaque psoriasis



    210mg once a week for three weeks. Reduce thereafter to 210mg once every two weeks.

    Consider discontinuing treatment if no response after 12 to 16 weeks of treatment. Patients with an initial partial response may improve if treatment is continued beyond 16 weeks.


    For subcutaneous injection only.


    Children under 18 years
    Severe infection
    Active Crohn's disease

    Precautions and Warnings

    Chronic infection
    History of recurrent infection
    Suicidal ideation
    History of depression
    Inactive Crohn's disease
    Inflammatory bowel disease
    Latent or healed tuberculosis

    Administration of live vaccines is not recommended
    Crohn's disease: Monitor patients closely as may cause exacerbation
    Discontinue if exacerbation of Crohn's disease
    Before starting therapy ensure immunisations are up to date
    Consider prophylactic anti-tuberculosis therapy if appropriate
    Treatment to be prescribed under the supervision of a specialist
    Avoid injection into areas of active skin disease
    Record name and batch number of administered product
    Warm to room temperature for 30-60 minutes before use
    Discontinue if signs and symptoms of inflammatory bowel disease occur
    Monitor for depressive disorders/suicidal ideation-consider discontinuation
    Advise patient to report any new or worsening depression/suicidal ideation
    Advise patient to report symptoms of infection immediately
    Consider discontinuing if depression develops
    Infants exposed in utero (3rd trimester): Use live vaccines with caution
    Consider discontinuing treatment if no response after 12-16 weeks
    Discontinue if serious allergic or anaphylactic reaction occurs
    Interrupt treatment if severe infection develops
    Female: Contraception required during and for 3 months after treatment

    Pregnancy and Lactation


    Brodalumab is contraindicated during pregnancy.

    The manufacturer does not recommend using brodalumab during pregnancy. At the time of writing there is limited published information regarding the use of brodalumab during pregnancy. Potential risks are unknown, however brodalumab is expected to cross the placenta.


    Brodalumab is contraindicated during breastfeeding.

    The manufacturer advises that the patient either discontinues brodalumab or discontinues breastfeeding. The presence of brodalumab in human breast milk is unknown but due to its large molecular weight, transfer is not expected. Effects on exposed infants are unknown.

    Side Effects

    Anaphylactic reaction
    Bruising at injection site
    Cryptococcosis infection
    Erythema at injection site
    Exacerbation of Crohn's disease
    Fungal infection
    Haemorrhage (injection site)
    Increased susceptibility to infection
    Inflammatory bowel disease
    Itching (injection site)
    Local pain (injection site)
    Oropharyngeal pain
    Reduced neutrophil count
    Respiratory tract infection
    Suicidal tendencies
    Tinea infections
    Tinea pedis
    Ulcerative colitis
    Urinary tract infections


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111.

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: October 2020

    Reference Sources

    Summary of Product Characteristics: Kyntheum 210mg Solution for Injection. Leo Laboratories Limited. Revised July 2020.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.